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Abstract
The gut virome consists of a large population of eukaryotic and prokaryotic 
viruses that have an emerging role in human health and disease. Growing  evidence 
for the importance of the virome includes recent findings on fecal virome trans-
plantation (FVT) that suggest FVT may have therapeutic potential for the resolu-
tion of dysbiosis and treatment of dysbiosis-related disorders. Most viruses in 
the gut virome are bacteriophages (phages), which have a well-established role in 
regulating bacterial communities across environments. Phages also influence health 
and disease by interacting directly with the host immune system. The full extent to 
which gut phages should be considered as both a target and a tool for microbiome 
modulation remains to be seen. This chapter will explore the current understanding 
of the gut virome and the therapeutic potential for FVT.
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1. Introduction
While the role of the bacterial community during fecal microbiota transplantation 
(FMT) has been the focus of extensive investigation, there has been substantially less 
examination of the viral community. The growing body of research on the viruses of 
the gut microbiome, referred to, herein, as the gut virome, points to their role as an 
important regulator of gut homeostasis [1–4]. This occurs through the modification 
of microbiome structure, composition, and function by gut bacteriophages [5–9], as 
well as through direct interaction between the enteric virome and the human immune 
system [4, 10–14]. In line with the gut virome’s regulatory role, several recent studies 
have shown that fecal virome transplantation (FVT), a procedure similar to FMT 
albeit filtered to exclude intact fecal bacteria, has potential for resolving gut microbi-
ome dysbiosis and restoring a healthy microbiota [15–18]. The full breadth of possi-
bilities for FVT are only now beginning to unfold, but this emerging field of study has 
produced exciting findings that suggest FVT may be a versatile therapeutic treatment 
for multiple forms of dysbiosis. Not only has FVT been used effectively for clinical 
treatment of Clostridium difficile infection (CDI), but promising preliminary results 
suggest FVT has potential for resolving other dysbiosis such as those associated with 
diabetes and small intestinal bacterial overgrowth. In this chapter we will be reviewing 
the current state of gut virome research and discussing the clinical potential for FVT.
2. The gut virome
The gut virome consists of a robust and diverse community of eukaryotic and 
bacterial viruses, with bacterial viruses (herein referred to as bacteriophages, 
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or phages) estimated to make up between 90% [19] and 97.7% [20] of the member-
ship of the gut virome. Approximately 1014 viruses, comprised of ~1200 virotypes, 
reside in the gastrointestinal tract at any given time [21], a population that is 
roughly 10 times that of gut bacteria but comparable in diversity [22, 23]. However, 
the ratio of phages to bacteria is approximately 1:1 in the infant gut suggesting the 
population changes over the course of development [24]. Like microbiome com-
position, virome composition is highly responsive to diet and when individuals are 
placed on the same diet, their viromes have been found to converge [25]. However, 
once established, the human gut virome has been shown to have high inter-indi-
vidual variation [26], sufficient enough for viromes to be distinguishable between 
related individuals, such as between infants and mothers [27]. Individual viromes 
are also stable over time and approximately 80% of gut viruses have been shown to 
persist over a 2.5 year period [28]. At the population level, metagenomic analysis 
of viromes has demonstrated that there is a core of shared viruses among viromes 
within a population that can be used to distinguish between other geographically 
distinct groups [29, 30]. Recent findings by Manrique and colleagues have sug-
gested that there is also a globally distributed set of core phages that are considered 
to constitute a “healthy gut phageome;” in part, because the prevalence of these 
phages is significantly decreased in the setting of inflammatory bowel disease (IBD; 
[31]. Specific phage community compositions and structures are associated with 
specific gastrointestinal and extraintestinal diseases including colon cancer [32], 
IBD [14, 33–36], rCDI [16, 37], and diabetes [15, 38].
3. Phages in the gut
As the dominant members of the gut virome, phages have been the focus of 
studies on the role of the gut virome in health and disease. Phages are ubiquitous 
viruses that are the most abundant biological entity in the world and can be found 
anywhere that bacteria can be found. Studying phages in the gut presents a number 
of difficulties. The first of which is that phages lack a universal marker, such as the 
16 s rRNA gene in bacteria. Second, since phages depend on their bacterial hosts 
for reproduction and only 39% of bacteria in the gut can be cultured [39], many 
phages that are associated with the other 61% cannot be cultivated. This means that 
modern phage research largely depends on costly and labor-intensive viral metage-
nomics, which also presents challenges due to the immense genetic diversity of 
phages, the lack of a robust virus metagenomic classification, and still nascent use 
of bioinformatics to evaluate data set generated from viral metagenomic analysis. 
Much phage research has revolved around the practice of phage therapy, which has 
been used for over 100 years in some Eastern European Countries to treat single 
strain bacterial infections. The emergence of antibiotic resistance has led to phages 
gaining recent attention for their potential as an alternative to antibiotics [40]. In 
phage therapy, patients are administered solutions of individual phage strains, or 
multiple strains (i.e. phage cocktail), which are selected through in vitro screening 
for their specificity to the single bacterial agent causing the infection and for their 
effectiveness in eliminating that one bacterial species. Much of the interest in phage 
therapy rather than antibiotics is based on the specificity of phages to target a nar-
row host range, allowing for the targeted elimination of a bacterial pathogen while 
leaving commensal bacterial members of the microbiome intact, and the ability of 
phages to self-propagate upon infection of their bacterial host.
In general, there are two types of phages: lytic and temperate. Lytic phages 
reproduce via the lytic cycle and temperate phages use the lysogenic cycle 




lifecycle, phages infect a bacterial host, hijack the host machinery for replication 
of viral progeny, and eventually lyse the host cell and the release of novel phage 
progeny. In the lysogenic lifecycle, a temperate phage infects a bacterial host and 
integrates its viral DNA into the bacterial chromosome as a prophage. This process 
does not always end in cell lysis, instead the prophage can reproduce by propagating 
with the bacterial chromosome during replication. Harmful environmental stimuli 
in the gut, such as oxidative stress [41], antibiotics [42], or other unfavorable condi-
tions for the bacterial host [43], can result in the induction of the prophage into the 
lytic cycle, thereby resulting in the lysis of the bacterial host and release of novel 
phage progeny. However, Lysogenic (temperate) phages are generally not used in 
phage therapy because lysogeny is a mechanism for bacteria to exchange DNA so 
lysogenic phages carry the potential for propagating genes for pathogenesis.
While lytic phages are largely seen as parasitic to their bacterial hosts, temper-
ate phages and their host bacteria have a much more complicated relationship. 
Temperate phages are important drivers of bacterial evolution [44], in part through 
their role in horizontal gene transfer between bacterial hosts. Temperate phages are 
common in the gut and studies have found that a large proportion of bacteria in the 
microbiome have temperate phages incorporated into their genomes as prophages 
[21, 45]. For the bacterial host, carrying prophages has several fitness benefits. 
Prophages encode genes for metabolism, antibacterial resistance, and toxin produc-
tion (for example, shiga toxin production) [9, 46], thereby conveying functional 
genes for survival to their bacterial hosts upon integration with the bacterial 
chromosome. Prophages also protect their hosts from infection by lytic phages 
through superinfection exclusion [47]. Phage-mediated horizontal gene transfer 
between bacterial hosts increases rates of genetic recombination and diversification 
of phage-encoded genes in the gut [48].
Composition, structure, and function of the gut virome contributes to health 
in a number of ways [49], as reviewed by Mukhopadhya and colleagues [50]. The 
coevolution between phages and their bacterial hosts is a well-established mecha-
nism for driving the development of microbial communities across environments 
[44]. This is also the case in the gut environment where phages are thought to 
modulate the microbiota and, in turn, affect human health. A longitudinal study of 
Figure 1. 
Reproductive lifecycles of phages.
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gut microbiome and virome composition in healthy infants found that expansion 
of gut bacterial species was accompanied by contractions and shifts of gut phage 
populations, suggesting that phage predation of targeted bacteria may help drive 
the development of a healthy infant gut microbiome [51]. Conversely, in the setting 
of dysbiosis, changes in the gut phage population have been shown to precede the 
onset of type 1 diabetes in children [38]. Phages are also thought to form a protec-
tive barrier in the mucosa of the gastrointestinal epithelium, thereby providing 
the host tissue with non-host-derived defense against pro-inflammatory gut 
bacteria [52]. Experimental evidence suggests that they do this by using their Ig-like 
domains expressed on the viral capsid to attach to the glycan molecules of the host’s 
mucin glycoproteins. Growing evidence now implicates a role for phages of the 
mucosa in states of dysbiosis, which have been characterized by an increased rich-
ness and abundance of the mucosal temperate phage population [9, 14, 34, 35, 53]. 
These changes in the phage community is opposite that of the bacterial community 
in which decreased richness and diversity characterize dysbiosis.
The virome also influences health through direct interaction with the human 
immune system by triggering both pro- and anti-inflammatory action [4, 10–14]. 
Phages are capable of activating TLR9-mediated IFNγ, a pro-inflammatory path-
way that exacerbates intestinal colitis [14]. Conversely, phages can also ameliorate 
inflammation through TLR3- and TLR4-mediated interferon-β activation [11]. 
Several studies have found elevated abundance of phages in the mucosal surfaces of 
patients with IBD [36, 53]. Other studies have found an expansion of phages from 
the order Caudovirales in the setting of inflammatory bowel disease [34, 54, 55]. 
Norman and colleagues speculate that phages may contribute to, or be a biomarker 
for, inflammation and dysbiosis in the gut. Collectively, these studies indicate that 
phages have an important role in gastrointestinal disorder and potentially, in the 
corrective response to dysbiosis.
4. Therapeutic potential for FVT
In the setting of FMT, a large population of phages is transferred from the FMT 
donor to recipient. Feces contain approximately 109 virus-like particles per gram, 
a density similar to that of fecal bacteria, and phages account for upwards of 90% 
of all fecal virus-like particles [19]. It follows that the large transfer of fecal phages 
during FMT could have a physiological effect on the FMT recipient. In attempting 
to examine the role of fecal phages during FMT, several recent studies have not 
only characterized a state of virome dysbiosis in the setting of recurrent C. difficile 
infection (rCDI), but also have shown that recovery is associated with uptake of a 
healthy virome from the FMT donor [16, 37, 56]. A study of one FMT patient found 
that the patient had adopted the donor’s phage community after 7 months, even 
when the patient’s microbiome maintained a dysbiotic composition. The micro-
biome resembled that of the healthy donor a year later [16]. This observation that 
the adoption of a ‘healthy’ phage community precedes resolution of dysbiosis may 
suggest a role for phages in promoting and maintaining a healthy microbiome. This 
possibility is further substantiated by Zuo and colleagues who found that successful 
recovery from rCDI after treatment with FMT was associated with a high level of 
colonization by the donor’s phage community in the recipient’s enteric virome [37]. 
Another study showing long-term stability of the FMT recipient’s virome found that 
the donor’s phage community maintained colonization of the recipient 12 months 
after treatment [56]. Similar findings have been observed in clinical trials for FMT 




Additional evidence for the active role of phages during FMT comes from stud-
ies on fecal virome transplantation (FVT) showing that the sub-bacterial fraction 
of a FMT (i.e. bacteria removed) can manipulate the composition and structure of a 
recipient’s microbiome [15, 18, 58]. One clinical study found that a fecal suspension 
that was filtered to remove bacteria, while leaving phages and other sub-bacterial 
particles intact, was sufficient for effective clinical treatment of rCDI and resto-
ration of a healthy microbiome [58]. Similarly, Kao and colleagues found that a 
sterilized fecal filtrate was sufficient for treating rCDI [59]. Using another clinically 
relevant model of dysbiosis, Rasmussen and colleagues demonstrated that a FVT 
from lean mice was effective at reducing weight and symptoms of diabetes type 2 
in obese mice fed a high-fat diet [15]. The investigators also showed that the FVT 
was able to increase bacterial diversity in the microbiome to the levels in lean mice. 
The ability for FVT to modulate microbiome composition is further supported by 
evidence showing that a FVT from high-fat diet-fed obese mice was sufficient for 
driving microbiome composition of healthy mice towards that of the high-fat diet 
donor [18]. The investigators also found that a FVT was sufficient for reducing 
small intestinal bacterial overgrowth (i.e. excess bacterial density in proximal small 
intestine) in obese mice to the level of healthy controls. In another recent study, 
investigators found that FVT also prevents necrotizing enterocolitis in preterm 
piglets [60]. Additionally, there is some speculation that the gut virome has a role 
in the “super-donor” phenomenon observed during FMT [61]. Collectively, these 
early studies demonstrate the therapeutic potential for FVT in multiple  settings of 
dysbiosis.
5. Dynamics of FVT-based modulation of the microbiome
The mechanisms through which FVT modifies the recipient’s gut microbiome is 
the subject of ongoing investigation and is likely the result of complex community 
interactions between donor phages and recipient bacteria, all of which is likely 
heavily influenced by the host gut environment. Temperate and lytic phages exhibit 
different population dynamics within microbial communities, and administration 
of individual strains of exogenous phages into the gastrointestinal tract of mice has 
been used to study these dynamics [5, 6, 62]. In a gnotobiotic mouse model where 
the gut is colonized by a defined community of resident gut bacteria, the adminis-
tration of monocultures of lytic phages exhibiting a narrow host range can reduce 
populations of their host bacteria through predation [5]. It was also observed that 
reducing targeted host bacteria subsequently leads to a cascading effect in which 
populations of non-host bacteria in the microbiome are affected through inter-
bacterial interactions. This effect propagated throughout the gut the microbiota 
with far-reaching consequences for the composition, structure, and function of the 
microbiota. Additionally, there is some evidence that a phage therapy approach has 
the potential to control or eliminate bacterial pathogens, such as Enterococcus faeca-
lis, in the gut [63]. These studies provide models for studying basic phage-bacterial 
dynamics in the gut, particularly ‘kill-the-winner’ population dynamics where lytic 
phages act as predators leading to a suppression of their bacterial hosts and opening 
of new ecological niches for non-host bacteria.
Since both temperate and lytic phages are transferred to the recipient during 
FMT and sustained in the recipient’s virome afterwards [17], it is likely that mul-
tiple population dynamics are at play in the setting of FVT. In a study using gnoto-
biotic mice with a defined microbiota, administration of a FVT from human feces 
resulted in a cascade of changing abundance of different gut bacteria that modeled 
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primarily that of temperate phage-bacteria dynamics [62]. In another study by Bao 
and colleagues, the investigators found that administration of lytic or temperate 
phage monocultures into the gut of healthy mice modulated the microbiome by 
changing relative abundances of host and non-host bacterial populations at both 
phylum and genus level [6]. Of note, in this particular study, lytic phages promoted 
a beneficial gut environment while temperate phages promoted conditions that 
would enable disease to occur. Other co-evolutionary phage-bacteria dynamics 
that have been observed in microbial communities include ‘piggyback-the-winner,’ 
‘arms-race,’ and ‘kill-the-relative’ dynamics, which are reviewed in detail elsewhere 
[2, 64]. Collectively, these dynamics are thought to contribute to the onset and 
maintenance of states of dysbiosis in the microbiome and are therefore also likely to 
have a role in recovery from dysbiosis in the setting of FVT. In the setting of rCDI, it 
is unclear whether exogenous phages with a broad host range down-regulate  
C. difficile populations or whether they promote a healthier microbiome with less 
ideal conditions for C. difficile colonization.
6. Safety considerations for FVT
While therapeutic application of FMT has been explored in many settings of 
dysbiosis [65–68], current clinical guidelines recommend that FMT should only 
be used as a last resort for rCDI due to the various safety concerns [69]. Much of 
the risk of FMT comes from the transfer of bacteria into an immuno-compromised 
recipient and the potential of inducing an unanticipated bacteria-driven phenotype 
(e.g., obesity). Accordingly, FVT may be associated with less risk due to the removal 
of intact bacteria prior to transplantation. However, since viruses are also capable 
of eliciting a pro-inflammatory response [12, 14], more research needs to be done to 
better understand how FVT interacts with the recipient host.
Safe clinical application of FVT will also require a deeper understanding of the 
viruses that comprise the gut virome. Numerous disease-causing viruses reside in 
the gut including herpesvirus, papillomaviruses, and hepatitis viruses. Sequencing 
of the virome has revealed numerous other viruses including bocaviruses, entero-
viruses, rotaviruses, and sapoviruses [28]. Many of these viruses have yet to be 
characterized and their function in the gut is unknown. Given the potential for 
infection by eukaryotic viruses, a thorough screening of the donor virome must be 
done to ensure that no harmful eukaryotic viruses are transferred into the recipient. 
The metagenome of the virome should also be screened since phages can encode 
genes for virulence factors (e.g., diphtheria toxin, shiga toxin, and botulinum toxin) 
and antibiotic resistance (e.g., β-lactamases) [70, 71].
Overall, the removal of bacteria is likely to make FVT a safer option than FMT. 
However, FVT still has safety considerations that must be better understood and 
effectively taken into account.
7. Conclusion
The emerging field of research focused on the gut virome is still in its infancy, 
in part due to the difficulty of studying viruses in the gut environment. However, 
similar to the field of microbiome research, recent work on the gut virome demon-
strates how previously overlooked inhabitants of the gut have a profound influence 
on, and are in fact inseparable from, health and disease. In the setting of FMT, 
the emerging association between uptake of the donor’s phage community and 
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characterized role in successful treatment of rCDI. Whether FVT will offer a safer 
or more effective alternative to FMT remains to be seen. We still have yet to deter-
mine the full therapeutic potential of FVT, but the promising preliminary findings 
on FVT suggest it may provide new treatment options for dysbiosis and dysbiosis-
associated disorders. Collectively, these recent advances argue for more attention 
to be given to FVT as a therapeutic tool for microbiome modulation and to the gut 
virome as a therapeutic target.
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